efgartigimod

Business news, market intelligence, and global industry analysis.

The Latest

Haleon plc invests £65M in Shanghai oral health plant as China becomes central to its global growth strategy

Haleon (NYSE, LSE: HLN) bets on China’s oral health boom with £65m Shanghai manufacturing facility

Could subcutaneous PD-1 therapy reshape oncology treatment logistics in China?

Cargo theft is rising across North America. Can Eagle Vision Security’s iFM platform stop it before it starts?

The hidden problem with GLP-1 weight loss and Veru Inc.’s bet to fix it (NASDAQ: VERU)

Representative image of FcRn-targeted biologics including nipocalimab and efgartigimod used in generalized myasthenia gravis treatment

How does nipocalimab compare to efgartigimod and rozanolixizumab? FcRn class battlelines in gMG and beyond

Compare nipocalimab, efgartigimod, and rozanolixizumab on efficacy, safety, dosing, pricing, and market strategy in generalized myasthenia gravis treatment.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

June 26, 2025